An Open-Label, First-In-Human Study Evaluating the Safety, Tolerability, and Efficacy of VC-02 Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness
Phase of Trial: Phase I/II
Latest Information Update: 25 Apr 2018
At a glance
- Drugs VC 02 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors ViaCyte Inc
- 05 Jan 2018 According to a ViaCyte Inc. media release, the first patients have been implanted in Cohort 2 with a potentially efficacious dose of the company's PEC-Direct islet cell replacement therapy in this trial.
- 07 Jul 2017 Status changed from not yet recruiting to recruiting.
- 19 May 2017 Status changed from planning to not yet recruiting.